BioVie Inc. (BIVI) Discusses Clinical Progress of Bezisterim Targeting Inflammation in Parkinson's, Alzheimer's, and Long COVID Transcript
Source: SeekingAlpha
2026-03-05 03:22:11 ET
BioVie Inc. (BIVI) Discusses Clinical Progress of Bezisterim Targeting Inflammation in Parkinson's, Alzheimer's, and Long COVID March 4, 2026 4:15 PM EST...
Read the full article on Seeking Alpha
For further details see:
BioVie Inc. (BIVI) Discusses Clinical Progress of Bezisterim Targeting Inflammation in Parkinson's, Alzheimer's, and Long COVID Transcript
BioVie Inc.
NASDAQ: BIVI
BIVI Trading
-1.47% G/L:
$1.34 Last:
20,372 Volume:
$1.37 Open:
BIVI Latest News
February 23, 2026 08:00:00 am
Join Biovie's Exclusive Live Investor Webinar and Q&A Session on March 4
February 12, 2026 08:00:00 am
BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting
January 08, 2026 08:00:00 am
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease
BIVI Stock Data
$8,825,978
7,475,679
24.33%
13
N/A
Biotechnology & Life Sciences
Healthcare
US
Carson City
